Skip to main content
. 2017 Jun 12;22(6):811–822. doi: 10.1007/s12192-017-0811-z

Table 1.

Main characteristics of the patients entered into the study

Patient Age Diagnosis Neoadjuvant chemotherapy Clinical response Pathological response Response to NCa
1 45 Squamous carcinoma Cisplatin 2B → 3A Poor Resistant
2 36 Squamous carcinoma Cisplatin 1B2 → 1B1 Good Sensitive
3 47 Adenocarcinoma Cisplatin 1B2 → 1B1 Poor Resistant
4 40 Squamous carcinoma Cisplatin 2B → 2B Poor Resistant
5 66 Squamous carcinoma Cisplatin 2B → 2A Good (NTa) Sensitive
6 47 Squamous carcinoma Cisplatin 2B → 4 Poor Resistant
7 39 Squamous carcinoma Cisplatin 1B2 → 1B2 Good Sensitive
8 39 Squamous carcinoma Cisplatin 2A → 1B1 Good Sensitive
9 39 Squamous carcinoma Cisplatin 2B → 2A1 Good (NT) Sensitive
10 67 Squamous carcinoma Cisplatin 3B → 3A Good Sensitive
11 39 Squamous carcinoma Cisplatin 2B → 2A1 Good Sensitive
12 47 Squamous carcinoma Cisplatin 2B → 4 Poor Resistant
13 40 Squamous carcinoma Cisplatin 3B → 4 Poor Resistant
14 46 Squamous carcinoma Cisplatin 2A → 1B Good (NT) Sensitive

aAbbreviation used: NC neoadjuvant chemotherapy, NT no tumor after cisplatin neoadjuvant chemotherapy